Project Grant R01AI189875
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $524,626 to the University of Wisconsin-Madison on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research titled "A Chromatin Loop Controls the Expression of Anterograde Transport Genes During HSV-1 Latency." The project, which extends through January 31, 2031, investigates the mechanisms governing herpes...
- Federal Grant Award Summary Louisiana State University received a $412,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 2, 2026 through January 31, 2028. The award supports research focused on identifying RNAi-independent antiviral genes through a biased genetic screen conducted in Caenorhabditis elegans (C. elegans), a model organism used in biomedical research....
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Kansas Center for Research Inc. a Project Grant of $411,499 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with completion scheduled for July 31, 2027. This research project seeks to establish poly(ADP-ribose) polymerase 14 (PARP14) as a novel host restriction factor that limits Herpes Simplex Virus 1 (HSV-1)...
- Federal Project Grant Award Summary Louisiana State University received a $392,409 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports research investigating immune manipulation mechanisms in Staphylococcus aureus colonization and infection, with particular focus on developing potential therapeutic interventions against...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Princeton University $133,600 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 24, 2025, with a completion date of March 31, 2027. This project grant supports investigator-initiated biomedical research into Herpes Simplex Virus Type 1 (HSV-1) infection mechanisms, specifically examining virus-induced chaperone enriched (VICE) domains and their role in...
- Federal Project Grant Award Summary Tufts University School of Medicine received a $243,600 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 23, 2026, with completion scheduled for January 31, 2028. The award supports investigator-initiated biomedical research focused on elucidating the mechanism by which the host factor CLCC1 (C1F5LNUF7W86) facilitates membrane fusion...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Connecticut Health Center a Project Grant totaling $263,375 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 20, 2026 through March 31, 2028. This award funds biomedical research investigating HSV (Herpes Simplex Virus) alkaline nuclease as a novel antiviral drug target. The research focuses on understanding the UL12 gene-encoded...
- Grant Award Summary The University of Pittsburgh received a $250,682 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 19, 2026, with a completion date of January 31, 2028. This research initiative investigates the role of nuclear paraspeckles and speckles in regulating Herpes Simplex Virus-1 (HSV-1) infection in human neurons and the establishment of viral latency. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arkansas for Medical Sciences $420,335 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 23, 2025, for a project period extending through May 31, 2027. The project investigates the role of lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses, specifically examining whether lytic gene expression drives the development and...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $232,558 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 13, 2026, with completion targeted for March 31, 2028. The grant funds research and development of an innovative gene therapy approach utilizing adeno-associated virus (AAV)-delivered meganucleases to achieve durable control of genital...
Louisiana State University Health Sciences Center-Shreveport received a $660,723 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of April 16, 2026, and a completion date of March 31, 2031. This investigator-initiated research project will deliver scientific investigation and knowledge generation focused on understanding the role of Z-form nucleic acid binding protein 1 (ZBP1) in controlling Herpes Simplex Virus Type 1 (HSV-1) pathogenesis. The research deliverables include three primary scientific objectives: (1) identifying Z-RNA ligands that activate ZBP1 and determining their formation mechanisms during HSV-1 infections; (2) elucidating how receptor-interacting protein kinase 1 (RIPK1) regulates ZBP1-driven RIPK3 activation; and (3) determining the role of ZBP1-activated cell death signaling, particularly necroptosis, in anti-HSV-1 host defense and pathogenesis using in vivo models. These studies will generate pioneering mechanistic insights into programmed cell death pathways initiated by ZBP1 during viral infection, contributing to fundamental understanding of viral pathogenesis and potential therapeutic targets for managing HSV-1 infections affecting the 67% of the global population with HSV-1 prevalence.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $660.7k | 4/17/26 |